Primary CNS Leiomyosarcoma in an Immunocompetent Patient [Case Report]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Polewski, P. J., Smith, A. L., Conway, P. D., Marinier, D. E. Tags: Management and treatment, Caregiver, Rhabdo & Other Soft Tissue Sarcomas Case Report Source Type: research
Communicating Value in Health Care Using Radar Charts: A Case Study of Prostate Cancer [CARE DELIVERY]
Conclusion:
Standardization and visualization of outcome and cost metrics may allow more comprehensive and collaborative discussions about the value of health care services. Communicating the value framework by using radar charts may be an effective method to present total value and the value of all outcomes and costs in a manner that is accessible to all stakeholders. Variations in plotting of costs and outcomes will require future focus group initiatives. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Thaker, N. G., Ali, T. N., Porter, M. E., Feeley, T. W., Kaplan, R. S., Frank, S. J. Tags: Quality of care, Affordable Care Act, Cost of care, Outcomes research, Surgery, Radiation, Cost Effectiveness, Outcomes Research, Quality of Care, Radiation Oncology, Radiation Oncology CARE DELIVERY Source Type: research
Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Ko, A. H. Tags: Management and treatment, Chemotherapy, Translational Oncology, Adult Medical Oncology COMMENTARIES Source Type: research
Is There Efficacy Beyond Cytotoxic Chemotherapy for Pancreatic Cancer? [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Kalyan, A., Benson, A. B. Tags: Combined Modality COMMENTARIES Source Type: research
Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? [Clinical Reviews]
At present, front-line therapy for metastatic pancreatic ductal adenocarcinoma is combination chemotherapy, most commonly FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) or gemcitabine and nanoparticle albumin-bound paclitaxel. Despite a better understanding of the genomic landscape and the importance of the tumor microenvironment, we have not made a seismic shift in the overall survival for this disease. Given our growing understanding of the biology of pancreatic ductal adenocarcinoma, the question remains whether novel, noncytotoxic agents will augment or even replace conventional chemotherapy. The thrust of ongo...
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Varadhachary, G. R., Wolff, R. A. Tags: Chemotherapy, Translational Oncology Clinical Reviews Source Type: research
Myelodysplastic Syndromes: Going Gently Into That Good Night [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Sekeres, M. A. Tags: Management and treatment, Leukemia, Chemotherapy COMMENTARIES Source Type: research
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This? [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Giralt, S. Tags: Leukemia COMMENTARIES Source Type: research
Hematopoietic Cell Transplantation for Myelodysplastic Syndromes [Clinical Reviews]
Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many older patients with comorbidities are poor HCT candidates, and treatment-related morbidity and mortality may offset benefit for patients with lower-risk disease. Consequently, selection of patients with MDS for HCT should take into consideration disease risk category including mutational status, HCT comorbidity index, functional status, donor options, and available institutional resources. Formal geriatric assessment may further guide use of HCT ...
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Bhatt, V. R., Steensma, D. P. Tags: Leukemia Clinical Reviews Source Type: research
Preoperative Therapy for Pancreatic Cancer: The Tide Is Turning [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Katz, M. H. G. Tags: Diagnosis & Staging, Surgery, Radiation, Chemotherapy, Combined Modality COMMENTARIES Source Type: research
Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma? [COMMENTARIES]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Hoffman, J. P., Reddy, S. S. Tags: Surgery, Chemotherapy, Combined Modality COMMENTARIES Source Type: research
Evolution of the Management of Resectable Pancreatic Cancer [Clinical Reviews]
In pancreatic cancer, as with many other solid tumors, a commonly held surgical adage—a chance to cut is a chance to cure—has been promulgated throughout the years. Following such reasoning, surgical extirpation of a localized tumor would prevent tumor dissemination and metastatic tumor progression. However, decades of surgical experience have demonstrated that surgical resection alone provides a limited median survival benefit. Despite the optimization of surgical technique and perioperative management over the past three decades, little progress has been made to improve the limited survival of patients with l...
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Tsai, S., Erickson, B. A., Dua, K., Ritch, P. S., Tolat, P., Evans, D. B. Tags: Clinical guidelines, Management and treatment, Clinical guidelines, Surgery, Surgical Oncology, Surgical Oncology Clinical Reviews Source Type: research
Completion of Therapy Talk [Editorials]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Wilejto, M., Grier, H., Shaikh, F. Tags: Communication, Doctor-patient communication, Survivorship, Communication, Doctor-patient communication, Practical Tips, Quality of care, Caregiver, Family member, Patient, Survivor, Training, Pediatric Oncology Editorials Source Type: research
What Adult Cancer Care Can Learn From Pediatrics [Editorials]
(Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - September 11, 2016 Category: Cancer & Oncology Authors: Brand, S. R., Pickard, L., Mack, J. W., Berry, L. L. Tags: Editorials Source Type: research
Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients [FOCUS ON QUALITY]
Conclusion:
Service use resulting from toxicity-related factors occurs frequently in community oncology settings. Monitoring toxicity patterns and outcomes can inform proactive symptom management approaches to reduce toxicity burden between scheduled visits. (Source: Journal of Oncology Practice)
Source: Journal of Oncology Practice - August 9, 2016 Category: Cancer & Oncology Authors: Harrison, J. M., Stella, P. J., LaVasseur, B., Adams, P. T., Swafford, L., Lewis, J., Mendelsohn-Victor, K., Friese, C. R. Tags: Complications of cancer and cancer treatment, Treatment related issues, Quality, Patient safety, Quality of care, Quality of Care FOCUS ON QUALITY Source Type: research
Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology [HEALTH POLICY]
Breakthrough therapy designation (BTD) is a new approach created by the US Congress and the US Food and Drug Administration (FDA) as part of the FDA Innovation and Safety Act of 2012 to expedite the drug development process for serious illness, including cancer. By law, to qualify for BTD, a new molecular entity must demonstrate substantial clinical improvement over existing therapies. Although the administrative requirements for granting BTD have been made available by the FDA, the actual trial designs, end points, and quantitative therapeutic thresholds involved in the granting process have not been made public. This lit...
Source: Journal of Oncology Practice - August 9, 2016 Category: Cancer & Oncology Authors: Kern, K. A. Tags: Methodology, Clinical guidelines, General public, Clinical Trials, Phase I and Clinical Pharmacology, Adult Medical Oncology HEALTH POLICY Source Type: research
